- November 30, 2020
- Posted by: Bastion team
- Category: Markets
- Moderna jumped 11% on Monday as the company prepared to file for US FDA approval of its coronavirus vaccine to be widely distributed.
- Studies conducted on 196 people show the vaccine shot is more than 94% effective at protecting people from becoming ill with the virus.
- Visit Business Insider’s homepage for more stories.
Shares in US drugmaker Moderna rose as much as 11% in pre-market trading on Monday after the company prepared to file for US regulatory approval for its COVID-19 vaccine candidate and as final data showed the shot was 94% effective.
More to come.
Bastion Balance Seoul, Korea.